Loading...

VERA VERA THERAPEUTICS INC Expansion Plans 8-K Filing

VR T

VR

VERA THERAPEUTICS INC

(VERA)

2025 8-K

FDA Alignment Update

Annual Meeting Results

Financial Results Update

Board Appointment

Financial Results Update

Management Change

Public Offering Announcement

Board Appointment

Clinical Trial Results

Financial Results Announced

Equity Offerings

Financial Statements

Debt-Equity Swaps

Clinical Trials

Financial Statements

Financial Results

Corporate Presentation

Financial Results

Public Offering

Financial Update

Study Expansion

Financial Results Announcement

Appointment of Chief Operat...

Appointment of Director

Financial Results Announcement

Results of Operations and F...

Public Offering

Financial Update

Clinical Trial Results

Departure of Chief Medical ...

Financial Results

Financial Results Announcement

Phase 2b ORIGIN clinical tr...

Annual Meeting Results

Financial Results Announcement

Earnings Report

Closure of Silicon Valley B...

Public Offering

Financial Update

Clinical Trial Update

Positive Clinical Trial Res...

External Links:

On November 6, 2025, Vera Therapeutics, Inc. reported that their drug atacicept achieved a 46% reduction in proteinuria in IgA nephropathy patients, with a significant 42% improvement compared to placebo. The study was highlighted at the ASN Kidney Week and revealed a favorable safety profile with fewer serious adverse events reported for atacicept than placebo.

AI Assistant

VERA THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.